Sepsis: Pathophysiology and clinical management

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Gotts, Jeffrey E ^a   Matthay, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY INTERVENTION; FLUID THERAPY; GENETIC VARIABILITY; HUMAN; INCIDENCE; INNATE IMMUNITY; LUNG VENTILATION; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TISSUE LEVEL; TREATMENT FAILURE; CLINICAL TRIAL (TOPIC); CROSS INFECTION; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; MORTALITY; NOMENCLATURE; PROCEDURES; SEVERITY OF ILLNESS INDEX; TRENDS;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FLUID THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 84971320866     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i1585     Document Type: Review

References (217)

1. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992;20:724-6. doi:10.1097/00003246-199206000-00002 pmid:1597021.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74. doi:10.1097/00003246-199206000-00025 pmid:1597042.
3. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801-10. doi:10.1001/jama.2016.0287. pmid:26903338.
4. Levy MM, Fink MP, Marshall JC, et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6. doi:10.1097/01.CCM.0000050454.01978.3B. pmid:12682500.
5. Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP. Incidence and prognostic value of the systemic inflammatory response syndrome and organ dysfunctions in ward patients. Am J Respir Crit Care Med 2015;192:958-64. doi:10.1164/rccm.201502-0275OC. pmid:26158402.
6. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013;381:774-5. doi:10.1016/S0140-6736(12)61815-7. pmid:23472921.
7. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005;11:56-63. doi:10.1016/j.molmed.2004.12.007. pmid:15694867.
8. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. doi:10.1097/00003246-200107000-00002 pmid:11445675.
9. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54. doi:10.1056/NEJMoa022139. pmid:12700374.
10. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-8. doi:10.1007/s00134-003-2136-x. pmid:14997295.
11. van Gestel A, Bakker J, Veraart CP, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. Crit Care 2004;8:R153-62. doi:10.1186/cc2858. pmid:15312213.
12. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006;10:R42. doi:10.1186/cc4854. pmid:16542492.
13. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16. doi:10.1001/jama.2014.2637. pmid:24638143.
14. Sakr Y, Elia C, Mascia L, et al. The influence of gender on the epidemiology of and outcome from severe sepsis. Crit Care 2013;17:R50. doi:10.1186/cc12570. pmid:23506971.
15. Wichmann MW, Inthorn D, Andress H-J, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 2000;26:167-72. doi:10.1007/s001340050041. pmid:10784304.
16. Adrie C, Azoulay E, Francais A, et al. OutcomeRea Study Group. Influence of gender on the outcome of severe sepsis: a reappraisal. Chest 2007;132:1786-93. doi:10.1378/chest.07-0420. pmid:17890473.
17. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: cardiovascular and immunological aspects. Virulence 2014;5:12-9. doi:10.4161/viru.26982. pmid:24193307.
18. Barnato AE, Alexander SL, Linde-Zwirble WT, Angus DC. Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics. Am J Respir Crit Care Med 2008;177:279-84. doi:10.1164/rccm.200703-480OC. pmid:17975201.
19. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Occurrence and outcomes of sepsis: influence of race. Crit Care Med 2007;35:763-8. doi:10.1097/01.CCM.0000256726.80998.BF. pmid:17255870.
20. Mayr FB, Yende S, Linde-Zwirble WT, et al. Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. JAMA 2010;303:2495-503. doi:10.1001/jama.2010.851. pmid:20571016.
21. Ferwerda B, Alonso S, Banahan K, et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A 2009;106:10272-7. doi:10.1073/pnas.0811273106. pmid:19509334.
22. Ferwerda B, McCall MBB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007;104:16645-50. doi:10.1073/pnas.0704828104. pmid:17925445.
23. Martin GSM, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006;34:15-21. doi:10.1097/01.CCM.0000194535.82812.BA. pmid:16374151.
24. Lemay ACB, Anzueto A, Restrepo MIM, Mortensen EM. Predictors of long-term mortality after severe sepsis in the elderly. Am J Med Sci 2014;347:282-8. doi:10.1097/MAJ.0b013e318295a147. pmid:23689053.
25. Brun-Buisson C, Doyon F, Carlet J, et al. French ICU Group for Severe Sepsis. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995;274:968-74. doi:10.1001/jama.1995.03530120060042. pmid:7674528.
26. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003;168:165-72. doi:10.1164/rccm.2201087. pmid:12851245.
27. Beale R, Reinhart K, Brunkhorst FM, et al. PROGRESS Advisory Board. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009;37:222-32. doi:10.1007/s15010-008-8203-z. pmid:19404580.
28. Tolsma V, Schwebel C, Azoulay E, et al. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. Chest 2014;146:1205-13. doi:10.1378/chest.13-2618. pmid:25033349.
29. Williams MD, Braun LA, Cooper LM, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004;8:R291-8. doi:10.1186/cc2893. pmid:15469571.
30. Rosolem MM, Rabello LSCF, Lisboa T, et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care 2012;27:301-7. doi:10.1016/j.jcrc.2011.06.014. pmid:21855281.
31. Zuber B, Tran T-C, Aegerter P, et al. CUB-Réa Network. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med 2012;40:55-62. doi:10.1097/CCM.0b013e31822d74ba. pmid:21926606.
32. Sørensen TIA, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-32. doi:10.1056/NEJM198803243181202. pmid:3347221.
33. Netea MG, van der Meer JWM. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011;364:60-70. doi:10.1056/NEJMra1001976. pmid:21208109.
34. Meyer NJM. Finding a needle in the haystack: leveraging bioinformatics to identify a functional genetic risk factor for sepsis death. Crit Care Med 2015;43:242-3. doi:10.1097/CCM.0000000000000664. pmid:25514715.
35. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010;14:R237. doi:10.1186/cc9392. pmid:21190579.
36. Clark MF, Baudouin SV. A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med 2006;32:1706-12. doi:10.1007/s00134-006-0327-y. pmid:16957907.
37. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-5. doi:10.1086/344893. pmid:12404174.
38. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028-32. doi:10.1001/archinte.162.9.1028. pmid:11996613.
39. Van der Graaf CA, Netea MG, Morré SA, et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006;17:29-34. pmid:16613760.
40. Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012;205:934-43. doi:10.1093/infdis/jir867. pmid:22301633.
41. Bochud P-Y, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77. doi:10.1056/NEJMoa0802629. pmid:18946062.
42. Henckaerts L, Nielsen KR, Steffensen R, et al. Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med 2009;37:192-201, e1-3. doi:10.1097/CCM.0b013e31819263d8. pmid:19050632.
43. Nakada TA, Russell JAM, Boyd JHM, Thair SA, Walley KR. Identification of a nonsynonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock. Crit Care Med 2015;43:101-8. doi:10.1097/CCM.0000000000000604. pmid:25188548.
44. Rautanen A, Mills TC, Gordon AC, et al. ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 2015;3:53-60. doi:10.1016/S2213-2600(14)70290-5. pmid:25533491.
45. O'Brien JMJM Jr, , Lu B, Ali NA, et al. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007;35:345-50. doi:10.1097/01.CCM.0000254340.91644.B2. pmid:17205003.
46. Henriksen DP, Pottegård A, Laursen CB, et al. Risk factors for hospitalization due to community-acquired sepsis - a population-based case-control study. PLoS One 2015;10:e0124838. doi:10.1371/journal.pone.0124838. pmid:25898024.
47. Calfee CSM, Matthay MA, Kangelaris KNM, et al. Cigarette smoke exposure and the acute respiratory distress syndrome. Crit Care Med 2015;43:1790-7. doi:10.1097/CCM.0000000000001089. pmid:26010690.
48. Calfee CS, Matthay MA, Eisner MD, et al. Active and passive cigarette smoking and acute lung injury after severe blunt trauma. Am J Respir Crit Care Med 2011;183:1660-5. doi:10.1164/rccm.201011-1802OC. pmid:21471091.
49. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Chronic medical conditions and risk of sepsis. PLoS One 2012;7:e48307. doi:10.1371/journal.pone.0048307. pmid:23118977.
50. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004;164:2206-16. doi:10.1001/archinte.164.20.2206. pmid:15534156.
51. Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 2010;65:77-81. doi:10.1136/thx.2009.123612. pmid:19996337.
52. Bello S, Menéndez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest 2014;146:1029-37. doi:10.1378/chest.13-2853. pmid:24811098.
53. Turan A, Mascha EJ, Roberman D, et al. Smoking and perioperative outcomes. Anesthesiology 2011;114:837-46. doi:10.1097/ALN.0b013e318210f560. pmid:21372682.
54. Blair LJ, Huntington CR, Cox TC, et al Risk factors for postoperative sepsis in laparoscopic gastric bypass. Surg Endosc 2015; published online 1 July. doi:10.1007/s00464-015-4349-9.
55. de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care 2014;18:660. doi:10.1186/s13054-014-0660-4. pmid:25475621.
56. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470. doi:10.1002/14651858.CD007470. pub3. pmid:24414552.
57. Georges S, Lepoutre A, Dabernat H, Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect 2013;141:1787-96. doi:10.1017/S0950268813000083. pmid:23425638.
58. Vincent J-L, Rello J, Marshall J, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9. doi:10.1001/jama.2009.1754. pmid:19952319.
59. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. BMJ 1996;312:1521-5. doi:10.1136/bmj.312.7045.1521 pmid:8646147.
60. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011;39:665-70. doi:10.1097/CCM.0b013e318206c1ca. pmid:21169817.
61. Hanberger H, Walther S, Leone M, et al. EPIC II Group of Investigators. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011;38:331-5. doi:10.1016/j.ijantimicag.2011.05.013. pmid:21798720.
62. Hanberger H, Antonelli M, Holmbom M, et al. EPIC II Group of Investigators. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infect Dis 2014;14:513. doi:10.1186/1471-2334-14-513. pmid:25245620.
63. De Waele J, Lipman J, Sakr Y, et al. EPIC II Investigators. Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infect Dis 2014;14:420. doi:10.1186/1471-2334-14-420. pmid:25074742.
64. Gustot T, Felleiter P, Pickkers P, et al. EPIC II Group of Investigators. Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study. Liver Int 2014;34:1496-503. doi:10.1111/liv.12520. pmid:24606193.
65. Weiss SL, Fitzgerald JC, Pappachan J, et al. Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med 2015;191:1147-57. doi:10.1164/rccm.201412-2323OC. pmid:25734408.
66. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 2013;14:686-93. doi:10.1097/PCC.0b013e3182917fad. pmid:23897242.
67. Rabuel C, Mebazaa A. Septic shock: a heart story since the 1960s. Intensive Care Med 2006;32:799-807. doi:10.1007/s00134-006-0142-5. pmid:16570145.
68. Kimchi A, Ellrodt AG, Berman DS, Riedinger MS, Swan HJ, Murata GH. Right ventricular performance in septic shock: a combined radionuclide and hemodynamic study. J Am Coll Cardiol 1984;4:945-51. doi:10.1016/S0735-1097(84)80055-8 pmid:6491086.
69. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984;100:483-90. doi:10.7326/0003-4819-100-4-483 pmid:6703540.
70. Shapiro NI, Howell MD, Talmor D, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524-8. doi:10.1016/j.annemergmed.2004.12.006. pmid:15855951.
71. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med 2014;371:2309-19. doi:10.1056/NEJMra1309483. pmid:25494270.
72. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22. doi:10.1056/NEJM199406163302404. pmid:7993413.
73. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77. doi:10.1056/NEJMoa010307. pmid:11794169.
74. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. Crit Care 2014;18:503. doi:10.1186/s13054-014-0503-3. pmid:25394679.
75. Ronco JJ, Fenwick JC, Tweeddale MG, et al. Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA 1993;270:1724-30. doi:10.1001/jama.1993.03510140084034 pmid:8411504.
76. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res 1980;47:301-11. doi:10.1161/01.RES.47.3.301 pmid:6996862.
77. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765-77. doi:10.1182/blood-2002-06-1887. pmid:12543869.
78. Koh IHJ, Menchaca-Diaz JL, Koh TH, et al. Microcirculatory evaluation in sepsis: a difficult task. Shock 2010;34(Suppl 1):27-33. doi:10.1097/SHK.0b013e3181e7e80c. pmid:20523273.
79. De Backer D, Ortiz JA, Salgado D. Coupling microcirculation to systemic hemodynamics. Curr Opin Crit Care 2010;16:250-4. doi:10.1097/MCC.0b013e3283383621. pmid:20179590.
80. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001;16:167-77. doi:10.1053/jcrc.2001.30666. pmid:11815902.
81. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012;122:2731-40. doi:10.1172/JCI60331. pmid:22850883.
82. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity 2014;40:463-75. doi:10.1016/j.immuni.2014.04.001. pmid:24745331.
83. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003;9:143-51. doi:10.1097/00075198-200304000-00011 pmid:12657978.
84. Schmid-Schönbein GW, Chang M. The autodigestion hypothesis for shock and multi-organ failure. Ann Biomed 2014;42:405-14. doi:10.1007/s10439-013-0891-6. pmid:23989761.
85. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock 2001;15:1-10. doi:10.1097/00024382-200115010-00001 pmid:11198350.
86. Doig CJ, Sutherland LR, Sandham JD, Fick GH, Verhoef M, Meddings JB. Increased intestinal permeability is associated with the development of multiple organ dysfunction syndrome in critically ill ICU patients. Am J Respir Crit Care Med 1998;158:444-51. doi:10.1164/ajrccm.158.2.9710092. pmid:9700119.
87. Walley KR, Francis GA, Opal SM, et al. The central role of proprotein convertase subtilisin/kexin type 9 in septic pathogen lipid transport and clearance. Am J Respir Crit Care Med 2015;192:1275-86. doi:10.1164/rccm.201505-0876CI. pmid:26252194.
88. Alobaidi R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-associated acute kidney injury. Semin Nephrol 2015;35:2-11. doi:10.1016/j.semnephrol.2015.01.002. pmid:25795495.
89. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008;36(Suppl):S198-203. doi:10.1097/CCM.0b013e318168ccd5. pmid:18382194.
90. Ishikawa K, May CN, Gobe G, Langenberg C, Bellomo R. Pathophysiology of septic acute kidney injury: a different view of tubular injury. Contrib Nephrol 2010;165:18-27. doi:10.1159/000313740. pmid:20427951.
91. Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med 2013;187:509-17. doi:10.1164/rccm.201211-1983OC. pmid:23348975.
92. Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol 2015;35:64-74. doi:10.1016/j.semnephrol.2015.01.007. pmid:25795500.
93. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009;9:418-28. doi:10.1038/nri2566. pmid:19461672.
94. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-62. doi:10.1038/35013070. pmid:10839541.
95. Ortiz-Pomales YT, Krzyzaniak M, Coimbra R, Baird A, Eliceiri BP. Vagus nerve stimulation blocks vascular permeability following burn in both local and distal sites. Burns 2013;39:68-75. doi:10.1016/j.burns.2012.04.004. pmid:22694873.
96. Van Westerloo DJ, Giebelen IA, Florquin S, et al. The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 2006;130:1822-30. doi:10.1053/j.gastro.2006.02.022. pmid:16697744.
97. Bernik TR, Friedman SG, Ochani M, et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg 2002;36:1231-6. doi:10.1067/mva.2002.129643. pmid:12469056.
98. Ziaja M. Septic encephalopathy. Curr Neurol Neurosci Rep 2013;13:383. doi:10.1007/s11910-013-0383-y. pmid:23954971.
99. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291:1753-62. doi:10.1001/jama.291.14.1753. pmid:15082703.
100. Pandharipande PP, Girard TD, Jackson JC, et al. BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med 2013;369:1306-16. doi:10.1056/NEJMoa1301372. pmid:24088092.
101. Iacobone E, Bailly-Salin J, Polito A, Friedman D, Stevens RD, Sharshar T. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med 2009;37(Suppl):S331-6. doi:10.1097/CCM.0b013e3181b6ed58. pmid:20046118.
102. Sharshar T, Carlier R, Bernard F, et al. Brain lesions in septic shock: a magnetic resonance imaging study. Intensive Care Med 2007;33:798-806. doi:10.1007/s00134-007-0598-y. pmid:17377766.
103. Schramm P, Klein KU, Falkenberg L, et al. Impaired cerebrovascular autoregulation in patients with severe sepsis and sepsisassociated delirium. Crit Care 2012;16:R181. doi:10.1186/cc11665. pmid:23036135.
104. Sharshar T, Annane D, de la Grandmaison GL, Brouland JP, Hopkinson NS, Françoise G. The neuropathology of septic shock. Brain Pathol 2004;14:21-33. doi:10.1111/j.1750-3639.2004.tb00494.x pmid:14997934.
105. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011;306:2594-605. doi:10.1001/jama.2011.1829. pmid:22187279.
106. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-63. doi:10.4049/jimmunol.166.11.6952 pmid:11359857.
107. Cabrera-Perez J, Condotta SA, Badovinac VP, Griffith TS. Impact of sepsis on CD4 T cell immunity. J Leukoc Biol 2014;96:767-77. doi:10.1189/jlb.5MR0114-067R. pmid:24791959.
108. Walton AH, Muenzer JT, Rasche D, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One 2014;9:e98819. doi:10.1371/journal.pone.0098819. pmid:24919177.
109. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 2014;42:383-91. doi:10.1097/SHK.0000000000000234. pmid:25051284.
110. Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011;15:R183. doi:10.1186/cc10332. pmid:21798063.
111. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med 2013;369:2126-36. doi:10.1056/NEJMra1208707. pmid:24283226.
112. Reade MC, Finfer S. Sedation and delirium in the intensive care unit. N Engl J Med 2014;370:444-54. doi:10.1056/NEJMra1208705. pmid:24476433.
113. Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. Am J Respir Crit Care Med 2010;182:446-54. doi:10.1164/rccm.201002-0210CI. pmid:20448093.
114. Moine P, Abraham E. Immunomodulation and sepsis: impact of the pathogen. Shock 2004;22:297-308. doi:10.1097/01.shk.0000140663.80530.73 pmid:15377883.
115. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4. doi:10.1126/science.3764421 pmid:3764421.
116. Dunn DL. Role of endotoxin and host cytokines in septic shock. Chest 1991;100(Suppl):164S-8S. doi:10.1378/chest.100.3-Supplement.164S pmid:1884642.
117. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4. doi:10.1038/330662a0. pmid:3317066.
118. Fisher CJ Jr, , Agosti JM, Opal SM, et al. The Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702. doi:10.1056/NEJM199606273342603. pmid:8637514.
119. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20. doi:10.1016/j.cell.2010.01.022. pmid:20303872.
120. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets - an updated view. Mediators Inflamm 2013;2013:165974. doi:10.1155/2013/165974. pmid:23853427.
121. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32. doi:10.1016/j.cell.2010.01.040. pmid:20303873.
122. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014;123:2768-76. doi:10.1182/blood-2013-10-463646. pmid:24366358.
123. Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticles - a new player in sepsis? Crit Care 2010;14:236. doi:10.1186/cc9231. pmid:21067540.
124. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45. doi:10.1038/nri3345. pmid:23222502.
125. Ward PA, Gao H. Sepsis, complement and the dysregulated inflammatory response. J Cell Mol Med 2009;13:4154-60. doi:10.1111/j.1582-4934.2009.00893.x. pmid:19725914.
126. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219-23. doi:10.1016/S0140-6736(02)09459-X. pmid:12133657.
127. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014;5:66-72. doi:10.4161/viru.26907. pmid:24185508.
128. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA 2013;310:1591-600. doi:10.1001/jama.2013.278481. pmid:24108501.
129. Hartl WH, Jauch K-W. Metabolic self-destruction in critically ill patients: origins, mechanisms and therapeutic principles. Nutrition 2014;30:261-7. doi:10.1016/j.nut.2013.07.019. pmid:24369911.
130. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013;13:722-37. doi:10.1038/nri3532. pmid:24064518.
131. Fullerton JN, O'Brien AJ, Gilroy DW. Pathways mediating resolution of inflammation: when enough is too much. J Pathol 2013;231:8-20. doi:10.1002/path.4232. pmid:23794437.
132. Levy BD, Serhan CN. Resolution of acute inflammation in the lung. Annu Rev Physiol 2014;76:467-92. doi:10.1146/annurevphysiol-021113-170408. pmid:24313723.
133. Talan DA, Guterman JJ, Overturf GD, Singer C, Hoffman JR, Lambert B. Analysis of emergency department management of suspected bacterial meningitis. Ann Emerg Med 1989;18:856-62. doi:10.1016/S0196-0644(89)80213-6 pmid:2757283.
134. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96. doi:10.1097/01.CCM.0000217961.75225.E9. pmid:16625125.
135. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749-55. doi:10.1097/CCM.0000000000000330. pmid:24717459.
136. Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med 2015;43:1907-15. doi:10.1097/CCM.0000000000001142. pmid:26121073.
137. Sivapalan P, Stæhr Jensen J-U. Timing of therapy in sepsis: are early antibiotics important for prognosis? Crit Care Med 2015;43:2030-1. doi:10.1097/CCM.0000000000001179. pmid:26274712.
138. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637. doi:10.1097/CCM.0b013e31827e83af. pmid:23353941.
139. Ronco JJ, Fenwick JC, Tweeddale MG. Does increasing oxygen delivery improve outcome in the critically ill? No. Crit Care Clin 1996;12:645-59. doi:10.1016/S0749-0704(05)70268-2 pmid:8839596.
140. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995;333:1025-32. doi:10.1056/NEJM199510193331601. pmid:7675044.
141. Maitland K, Kiguli S, Opoka RO, et al. FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011;364:2483-95. doi:10.1056/NEJMoa1101549. pmid:21615299.
142. Perner A, Haase N, Guttormsen AB, et al. 6S Trial Group Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34. doi:10.1056/NEJMoa1204242. pmid:22738085.
143. Yealy DM, Kellum JA, Huang DT, et al. ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-93. doi:10.1056/NEJMoa1401602. pmid:24635773.
144. Peake SL, Delaney A, Bailey M, et al. ARISE Investigators ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014;371:1496-506. doi:10.1056/NEJMoa1404380. pmid:25272316.
145. Caironi P, Tognoni G, Masson S, et al. ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014;370:1412-21. doi:10.1056/NEJMoa1305727. pmid:24635772.
146. Asfar P, Meziani F, Hamel J-F, et al. SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014;370:1583-93. doi:10.1056/NEJMoa1312173. pmid:24635770.
147. Holst LB, Haase N, Wetterslev J, et al. TRISS Trial Group Scandinavian Critical Care Trials Group. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381-91. doi:10.1056/NEJMoa1406617. pmid:25270275.
148. Mouncey PR, Osborn TM, Power GS, et al. ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301-11. doi:10.1056/NEJMoa1500896. pmid:25776532.
149. Young P, Bailey M, Beasley R, et al. SPLIT Investigators ANZICS CTG. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 2015;314:1701-10. doi:10.1001/jama.2015.12334. pmid:26444692.
150. Levy MM, Dellinger RP, Townsend SR, et al. Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010;38:367-74. doi:10.1097/CCM.0b013e3181cb0cdc. pmid:20035219.
151. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ 2014;349:g4561. doi:10.1136/bmj.g4561 pmid:25099709.
152. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012;308:1566-72. doi:10.1001/jama.2012.13356. pmid:23073953.
153. Greenfield N, Balk RA. Evaluating the adequacy of fluid resuscitation in patients with septic shock: controversies and future directions. Hosp Pract (1995) 2012;40:147-57. doi:10.3810/hp.2012.04.980. pmid:22615089.
154. Wiedemann HP, Wheeler AP, Bernard GR, et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-75. doi:10.1056/NEJMoa062200. pmid:16714767.
155. Vincent J-L, Sakr Y, Sprung CL, et al. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53. doi:10.1097/01.CCM.0000194725.48928.3A pmid:16424713.
156. de Oliveira FSV, Freitas FGR, Ferreira EM, et al. Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock. J Crit Care 2015;30:97-101. doi:10.1016/j.jcrc.2014.09.002. pmid:25269788.
157. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010;303:739-46. doi:10.1001/jama.2010.158. pmid:20179283.
158. Funk DJ, Jacobsohn E, Kumar A. Role of the venous return in critical illness and shock: part II-shock and mechanical ventilation. Crit Care Med 2013;41:573-9. doi:10.1097/CCM.0b013e31827bfc25. pmid:23263572.
159. Persichini R, Silva S, Teboul J-L, et al. Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med 2012;40:3146-53. doi:10.1097/CCM.0b013e318260c6c3. pmid:22926333.
160. Waechter J, Kumar A, Lapinsky SE, et al. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Interaction between fluids and vasoactive agents on mortality in septic shock: a multicenter, observational study. Crit Care Med 2014;42:2158-68. doi:10.1097/CCM.0000000000000520. pmid:25072761.
161. Havel C, Arrich J, Losert H, Gamper G, Müllner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2011;5:CD003709. doi:10.1002/14651858.CD003709.pub3. pmid:21563137.
162. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012;40:725-30. doi:10.1097/CCM.0b013e31823778ee. pmid:22036860.
163. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8. doi:10.1056/NEJM200005043421801. pmid:10793162.
164. Eisner MD, Thompson T, Hudson LD, et al. Acute Respiratory Distress Syndrome Network. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:231-6. doi:10.1164/ajrccm.164.2.2011093. pmid:11463593.
165. Kollef MH, Levy NT, Ahrens TS, Schaiff R, Prentice D, Sherman G. The use of continuous iv sedation is associated with prolongation of mechanical ventilation. Chest 1998;114:541-8. doi:10.1378/chest.114.2.541 pmid:9726743.
166. Shehabi Y, Bellomo R, Reade MC, et al. Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators ANZICS Clinical Trials Group. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med 2012;186:724-31. doi:10.1164/rccm.201203-0522OC. pmid:22859526.
167. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7. doi:10.1056/NEJM200005183422002. pmid:10816184.
168. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009;373:1874-82. doi:10.1016/S0140-6736(09)60658-9. pmid:19446324.
169. Fernandez JF, Levine SM, Restrepo MI. Technologic advances in endotracheal tubes for prevention of ventilator-associated pneumonia. Chest 2012;142:231-8. doi:10.1378/chest.11-2420. pmid:22796845.
170. Shi Z, Xie H, Wang P, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Cochrane Database Syst Rev 2013;8:CD008367. doi:10.1002/14651858.CD008367.pub2. pmid:23939759.
171. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281:261-7. doi:10.1001/jama.281.3.261 pmid:9918482.
172. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32. doi:10.1056/NEJMoa061115. pmid:17192537.
173. Galiczewski JM. Interventions for the prevention of catheter associated urinary tract infections in intensive care units: an integrative review. Intensive Crit Care Nurs 2016;32:1-11. doi:10.1016/j.iccn.2015.08.007. pmid:26604039.
174. Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007;102:412-29, quiz 468. doi:10.1111/j.1572-0241.2006.01024.x. pmid:17311654.
175. Rice TW, Wheeler AP, Thompson BT, et al. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA 2012;307:795-803. doi:10.1001/jama.2012.137. pmid:22307571.
176. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011;365:506-17. doi:10.1056/NEJMoa1102662. pmid:21714640.
177. Finfer S, Chittock DR, Su SY, et al. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97. doi:10.1056/NEJMoa0810625. pmid:19318384.
178. Fraser GL, Devlin JW, Worby CP, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013;41 (Suppl 1): S30-8. doi:10.1097/CCM.0b013e3182a16898. pmid:23989093.
179. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E. Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009;37:803-10. doi:10.1097/CCM.0b013e3181962316. pmid:19237881.
180. Borthwick EMJ, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B. High-volume haemofiltration for sepsis. Cochrane Database Syst Rev 2013;1:CD008075. doi:10.1002/14651858.CD008075.pub2. pmid:23440825.
181. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41. doi:10.1097/00000658-197609000-00011 pmid:786190.
182. Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 2012;185:133-9. doi:10.1164/rccm.201011-1897CI. pmid:21680949.
183. Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med 2013;41:2419-29. doi:10.1097/CCM.0b013e3182982add. pmid:23887234.
184. Panacek EA, Marshall JC, Albertson TE, et al. Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32:2173-82. doi:10.1097/01.CCM.0000145229.59014.6C pmid:15640628.
185. Fisher CJ Jr, , Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-43. doi:10.1001/jama.1994.03510470040032 pmid:8196140.
186. Opal SM, Fisher CJ Jr, , Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115-24. doi:10.1097/00003246-199707000-00010 pmid:9233735.
187. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5. doi:10.7326/0003-4819-121-1-199407010-00001 pmid:8198341.
188. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000;283:1723-30. doi:10.1001/jama.283.13.1723 pmid:10755499.
189. Opal SM, Laterre P-F, Francois B, et al. ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62. doi:10.1001/jama.2013.2194. pmid:23512062.
190. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. doi:10.1056/NEJM200103083441001. pmid:11236773.
191. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006;355:1640-2. doi:10.1056/NEJMp068197. pmid:17050887.
192. Ranieri VM, Thompson BT, Barie PS, et al. PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64. doi:10.1056/NEJMoa1202290. pmid:22616830.
193. Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007;335:1248-51. doi:10.1136/bmj.39398.682500.25. pmid:18037615.
194. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78. doi:10.1001/jama.286.15.1869 pmid:11597289.
195. Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009;37:1185-96. doi:10.1097/CCM.0b013e31819c06bc. pmid:19242322.
196. Root RK, Lodato RF, Patrick W, et al. Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003;31:367-73. doi:10.1097/01.CCM.0000048629.32625.5D. pmid:12576938.
197. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-8. doi:10.1164/rccm.200903-0363OC. pmid:19590022.
198. Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Rev Drug Discov 2014;13:741-58. doi:10.1038/nrd4368. pmid:25190187.
199. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195-203. doi:10.1016/j.molmed.2014.01.007. pmid:24581450.
200. Vincent J-L, Martinez EO, Silva E. Evolving concepts in sepsis definitions. Crit Care Nurs Clin North Am 2011;23:29-39. doi:10.1016/j.ccell.2010.12.002. pmid:21316566.
201. Munford RS. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol 2006;1:467-96. doi:10.1146/annurev.pathol.1.110304.100200. pmid:18039123.
202. Drazen JM. Transparency for clinical trials - the TEST Act. N Engl J Med 2012;367:863-4. doi:10.1056/NEJMe1209433. pmid:22873430.
203. Calvano SE, Xiao W, Richards DR, et al. Inflamm and Host Response to Injury Large Scale Collab. Res. Program. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-7. doi:10.1038/nature03985. pmid:16136080.
204. Kamisoglu K, Sleight KE, Calvano SE, Coyle SM, Corbett SA, Androulakis IP. Temporal metabolic profiling of plasma during endotoxemia in humans. Shock 2013;40:519-26. doi:10.1097/SHK.0000000000000063. pmid:24089011.
205. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-20. doi:10.1016/S2213-2600(14)70097-9. pmid:24853585.
206. Seok J, Warren HS, Cuenca AG, et al. Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013;110:3507-12. doi:10.1073/pnas.1222878110. pmid:23401516.
207. Osuchowski MF, Remick DG, Lederer JA, et al. Abandon the mouse research ship? Not just yet! Shock 2014;41:463-75. doi:10.1097/SHK.0000000000000153. pmid:24569509.
208. Efron PA, Mohr AM, Moore FA, Moldawer LL. The future of murine sepsis and trauma research models. J Leukoc Biol 2015;98:945-52. doi:10.1189/jlb.5MR0315-127R. pmid:26034205.
209. Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013;79:294-8. pmid:23241735.
210. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91. doi:10.1001/jama.2013.278477. pmid:24108526.
211. Mehta D, Ravindran K, Kuebler WM. Novel regulators of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 2014;307:L924-35. doi:10.1152/ajplung.00318.2014. pmid:25381026.
212. Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol 2014;7:a016311. doi:10.1101/cshperspect.a016311. pmid:25359497.
213. Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells 2015;7:368-79. doi:10.4252/wjsc.v7.i2.368. pmid:25815121.
214. Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care 2014;4:22. doi:10.1186/s13613-014-0022-z. pmid:25593740.
215. Esposito S, Durando P, Bosis S, Ansaldi F, Tagliabue C, Icardi G. ESCMID Vaccine Study Group (EVASG). Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med 2014;25:203-12. doi:10.1016/j.ejim.2013.12.004. pmid:24389370.
216. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73. doi:10.1097/01.CCM.0000117317.18092. E4 pmid:15090974.
217. Abraham E. New definitions for sepsis and septic shock: continuing evolution but with much still to be done. JAMA 2016;315:757-9. doi:10.1001/jama.2016.0290. pmid:26903333.